A peptidic compound having the formula: R 1 -Z-R 2 wherein Z is a peptide moiety having the formula X2 represents an amino acid residue selected from Ser, D-Ser and Aib, X3 represents an amino acid residue selected from Gln, His and α-amino-functionalized Gln, wherein Gln may be functionalized in that an H of the α-NH 2 group is substituted by (C 1 -C 4)-alkyl, X14 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the -NH 2 side chain group is functionalized by -C -R 5, X15 represents an amino acid residue selected from Glu and Asp, X16 represents an amino acid residue selected from Ser, Lys and Glu, X17 represents an amino acid residue selected from Arg, Glu, Gln, Leu and Lys, X18 represents an amino acid residue selected from Arg and Ala, X20 represents an amino acid residue selected from Gln, Arg, Lys and Aib, X21 represents an amino acid residue selected from Asp, Leu and Glu, X28 represents an amino acid residue selected from Asn, Arg, Lys, Aib, Ser, Glu, Asp and Ala, X29 represents an amino acid residue selected from Gly, Ala, D-Ala and Thr, X35 represents an amino acid residue selected from Ala or Glu, X39 is Ser or is absent, X40 is either absent or represents Lys, wherein the -NH 2 side chain group can be functionalized by -C -R 5 and R 5 is a lipophilic moiety selected from an acyclic linear or branched (C 4 -C 30) saturated or unsaturated hydrocarbon group, and/or a cyclic saturated, unsaturated or aromatic group, wherein the lipophilic moiety may be attached to the -NH 2 side chain group by a linker selected from (β-Ala) 1-4, (γ-Glu) 1-4, (ε-Ahx) 1-4, or (GABA) 1-4 in all stereoisomeric forms; R 1 represents the N-terminal group of the peptidic compound and is selected from NH 2 and mono- or bisfunctionalized NH 2, R 2 represents the C-terminal group of the peptidic compound and is selected from (i) OH or functionalized OH and (ii) NH 2 or mono- or bisfunctionalized NH 2, or a salt or solvate thereof, and wherein the compound is a dual GLP-1 and glucagon receptor agonist. X2 represents an amino acid residue selected from Ser, D-Ser and Aib, X3 represents an amino acid residue selected from Gln, His and α-amino-functionalized Gln, wherein Gln may be functionalized in that an H of the α-NH 2 group is substituted by (C 1 -C 4)-alkyl, X14 represents an amino acid residue selected from Lys, Orn, Dab and Dap, wherein the -NH 2 side chain group is functionalized by -C -R 5, X15 represents an amino acid residue selected from Glu and Asp, X16 represents an amino acid residue selected from Ser, Lys and Glu, X17 represents an amino acid residue selected from Arg, Glu, Gln, Leu and Lys, X18 represents an amino acid residue selected from Arg and Ala, X20 represents an amino acid residue selected from Gln, Arg, Lys and Aib, X21 represents an amino acid residue selected from Asp, Leu and Glu, X28 represents an amino acid residue selected from Asn, Arg, Lys, Aib, Ser, Glu, Asp and Ala, X29 represents an amino acid residue selected from Gly, Ala, D-Ala and Thr, X35 represents an amino acid residue selected from Ala or Glu, X39 is Ser or is absent, X40 is either absent or represents Lys, wherein the -NH 2 side chain group can be functionalized by -C -R 5 and R 5 is a lipophilic moiety selected from an acyclic linear or branched (C 4 -C 30) saturated or unsaturated hydrocarbon group, and/or a cyclic saturated, unsaturated or aromatic group, wherein the lipophilic moiety may be attached to the -NH 2 side chain group by a linker selected from (β-Ala) 1-4, (γ-Glu) 1-4, (ε-Ahx) 1-4, or (GABA) 1-4 in all stereoisomeric forms; R 1 represents the N-terminal group of the peptidic compound and is selected from NH 2 and mono- or bisfunctionalized NH 2, R 2 represents the C-terminal group of the peptidic compound and is selected from (i) OH or functionalized OH and (ii) NH 2 or mono- or bisfunctionalized NH 2, (i) OH or functionalized OH and (ii) NH 2 or mono- or bisfunctionalized NH 2,